NysnoBio

[NysnoBio @NysnoBio]

NysnoBio announces addt'l funding from @MichaelJFoxOrg to advance their Parkin gene therapy development candidate NB001 towards IND status in prep for human clinical trials! https://t.co/eEcdroLBjD #PD #genetherapy #parkin

[NysnoBio @NysnoBio]

NysnoBio is proud to be working with Dr. Eidelberg to develop additional patterns that define specific subtypes of PD in our efforts to create a new paradigm to advance promising therapeutics.
#genetherapy #parkinsonsdisease
https://t.co/R5I9OlNW6W

[NysnoBio @NysnoBio]

NysnoBio announces the addition of Christina Gamba-Vitalo, PhD, to our leadership team! Christina’s expertise using intraparenchymal delivery of gene therapies for Parkinson’s Disease and other neurodegenerative disorders will help guide our programs to the clinic. 💪

[NysnoBio @NysnoBio]

Honored to be featured—and to share some of our discovery work that helps drive our clinical innovations! #parkin #genetherapy
https://t.co/3lTzgJrdl7 | https://t.co/jkOQh5AW5y

[Illumina @illumina]

Meet the team at @NysnoBio taking a novel approach to #Parkinson’s disease research. They’re seeking a therapy to replace the Parkin #gene in people who are missing it to arrest the progression of the disease in patients. https://t.co/6r0p5zmjTB

[NysnoBio @NysnoBio]

Dr. Malú Gámez Tansey joins our SAB! She brings 20+ years of pioneering work on inflammation and mechanisms of neurodegeneration to enrich and expand the scope of our pipeline for PD therapeutics and clinical translational biomarkers. Welcome Malú! #parkinsonsdisease #genetherapy

[NysnoBio @NysnoBio]

Our CEO, Jennifer Johnston, PhD will be in Boston leading the workshop on E3 Ligase Biology at 5th Annual TPD on Tuesday, October 25th. Bonus: workshops are streamed!
https://t.co/EysOJ3QmPQ
https://t.co/3lTzgJrLaF

[NysnoBio @NysnoBio]

NysnoBio's presenting at the MJFF's 14th Annual PD Therapeutics Conference. CEO Dr. Jennifer Johnston will discuss our powerful clinical advancement strategy for our Parkin-based gene therapy for PD! 💪 #parkinsonsdisease #parkin https://t.co/ANKl7mNOmE

[NysnoBio @NysnoBio]

Liz Higgins has been promoted to CTO at NysnoBio! Liz has established the strategic path and precision focus on the highest standards in safety and quality to move our gene therapy pipeline to critical IND-enabling studies over the coming year. Congrats! https://t.co/3lTzgJrdl7

[NysnoBio @NysnoBio]

Congrats to Prof. Nobutaka Hattori, member of NysnoBio's esteemed SAB, on your award for Outstanding Scholar and Role-Model Clinician in the Field! Prof. Hattori will be recognized this Friday at the MDS Presidential Lectures in Madrid.
https://t.co/LPbosNIuHF

[NysnoBio @NysnoBio]

Exciting advances in YOPD research! NysnoBio CEO Jennifer Johnston, PhD, discusses challenges and options that are specific to Young Onset Parkinson's disease patients at this YOPN virtual event. REGISTER NOW. https://t.co/yeBEcrX2rR

[NysnoBio @NysnoBio]

New Insight! 💡 NysnoBio SAB member Professor Nobutaka Hattori has published new insight into Parkin activation, and NysnoBio is advancing a potential biomarker based on this work. https://t.co/9bCwRKxxy6

[NysnoBio @NysnoBio]

NYSNOBIO AWARDED MICHAEL J. FOX FOUNDATION GRANT FOR FIRST CLINICAL STUDY https://t.co/mJE3yiPqDj

[NysnoBio @NysnoBio]

Our busy CEO, Dr. Jennifer Johnston, is doing double duty at the 2nd Annual Ligase Targeting Drug Development virtual summit this week! https://t.co/3lTzgJrdl7 https://t.co/oB29uLgCr7

[NysnoBio @NysnoBio]

NysnoBio's at the CHI Gene Therapy Summit in Boston this week! https://t.co/3lTzgJrdl7
https://t.co/6XXAJnk09p
#genetherapy #precisionmedicine #clinicaltrials

[NysnoBio @NysnoBio]

Dr. Leonard Post joins our SAB! Dr. Post's pioneering work advancing gene therapy programs through the clinic makes him a key addition as we advance our genetic medicines towards defined patient populations in need of novel therapies. #parkinsonsdisease #parkin #genetherapy

[NysnoBio @NysnoBio]

NysnoBio and several of the world’s top Parkin-linked Parkinson’s clinicians converge on Feb 10th to advance the cause: actively building a Parkin-specific patient profile as we move toward Phase 1 trials in this group of early-onset, genetically linked PD patients. PROGRESS! 💪

[NysnoBio @NysnoBio]

NysnoBio's at Pacifichem 2021! A fully-virtual Congress this year, don't miss Jennifer Johnston, PhD, Cofounder and CEO of NysnoBio, on Fri at 10:35 PST as she discusses small molecule activation of Parkin E3 ubiquitin ligase. https://t.co/3lTzgJrdl7 #parkinsonsdisease #parkin

[NysnoBio @NysnoBio]

NysnoBio's in the semi-finals of the BioPitch competition at BioFlorida! Tomorrow our CEO, Jennifer Johnston, is one of just 16 who will vie for a spot in Friday's finals. Go, JJ! 💪 https://t.co/PAIYulIFBr
https://t.co/ANKl7mNgx6
#parkinsonsdisease #parkin #lifesciences

[NysnoBio @NysnoBio]

Pioneering Research in E3 Ubiquitin Ligase Biology and Applications to Drug Discovery https://t.co/UEP7TILzxH

[NysnoBio @NysnoBio]

Washington Post Health: Professor J. William Langston, NysnoBio Scientific Advisory Board (SAB) Member, discusses susceptibility to Parkinson's disease.
https://t.co/PryZSfC8XR